Bluejay Diagnostics Advances Rapid Biomarker Testing For Sepsis Patients
Bluejay Diagnostics released baseline data from its SYMON-II study, evaluating the IL-6 biomarker for mortality risk in sepsis patients.
Stocks · News reference
Bluejay Diagnostics Q2 EPS $(1.12) Up From $(5.64) YoY
Bluejay Diagnostics (NASDAQ:BJDX) reported quarterly losses of $(1.12) per share. This is a 80.14 percent increase over losses of $(5.64) per share from the same period last year.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Bluejay Diagnostics, Inc. (BJDX)
Filed: 2026-10-06 AccNo: 0001213900-26-106999 Size: 252 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Bluejay Diagnostics Reports SYMON-II Baseline Data Showing Diverse Critically Ill Sepsis Population And Meaningful Mortality Events Supporting IL-6 Evaluation For 28-Day Mortality Risk
SYMON-II Clinical Validation Dataset Represents a Key Milestone as Bluejay Advances the Symphony™ IL-6 Test Toward Regulatory SubmissionACTON, MA / ACCESS Newswire / October 6, 2026 / Bluejay Diagnostics, Inc.
Bluejay Diagnostics shares are trading higher after the company announced a strategic partnership with Lovell Government Services to support the introduction of its products into the federal healthcare market.